<DOC>
	<DOCNO>NCT01054729</DOCNO>
	<brief_summary>Participants genotype 1 HCV infection randomize 1 3 sofosbuvir dos ( 100 mg , 200 mg , 400 mg ) match placebo daily base upon stratification IL28B status ( CC CT/TT ) . Placebo tablet administer participant receive 100 mg active sofosbuvir ( 3 placebo tablet ) 200 mg active sofosbuvir ( 2 placebo tablet ) order maintain study blind . Participants receive sofosbuvir/matching placebo Day 0 27 . Participants also receive treatment PEG+RBV start Day 0 study continue 48 week . Participants evaluate sustained virologic response ( SVR ) additional 24 week follow completion study treatment .</brief_summary>
	<brief_title>Dose-Ranging Study Sofosbuvir Combination With Pegylated Interferon Ribavirin Treatment Na√Øve GT 1 HCV Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Treatmentnaive male female , 1865 year age Genotype 1 HCV infection Negative pregnancy test female childbearing age Females childbearing age male female partner childbearing age must use two form contraception treatment follow last dose ribavirin accordance locally approve label ribavirin Hepatitis B HIV infection Pregnant breast feeding female male partner pregnant female Previous interferon ribavirinbased therapy investigational antiHCV agent History evidence medical condition associate chronic liver disease HCV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Chronic Hepatitis C infection Genotype 1</keyword>
	<keyword>HCV</keyword>
	<keyword>GT1</keyword>
	<keyword>GT 1</keyword>
</DOC>